Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Feasibility × pertuzumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 141 HER2-positive Breast Cancer 15 Neoplasms 11 Neoplasm Metastasis 8 Carcinoma, Non-Small-Cell Lung 6 Prostatic Neoplasms 5 Ovarian Neoplasms 5 Stomach Neoplasms 4 Inflammatory Breast Neoplasms 4 Colonic Neoplasms 4 Brain Neoplasms 4 Triple Negative Breast Neoplasms 3 Solid Tumor 3 Pathologic Complete Response 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Endometrial Neoplasms 3 Breast Neoplasms, Male 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Rectal Neoplasms 2 Locally Advanced Breast Cancer 2 Hematologic Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 HER2-positive Early Breast Cancer 2 Gastrointestinal Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Ductal, Breast 2 Anatomic Stage II Breast Cancer AJCC v8 2

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡